6766网站澳门联合娱乐官网平台

公司簡介

6766网站澳门联合娱乐官网平台成立于2008年4月，是一家位于上海浦東張江高科技園區，集研發、生産、銷售為一體的高新技術企業。公司主要從事生物藥物、新型診斷試劑的研發、生産、銷售和技術服務，于2012年12月在新三闆上市（股票名稱：6766网站澳门联合娱乐官网平台，股票代碼：430175），擁有北京金豪制藥股份有限公司、中山瑞福醫療器械科技有限公司和中山瑞福醫療器械研究有限公司三家子公司。2015年，在新三闆“最有價值和最具創新力企業”評選中，公司從數千家企業中脫穎而出，被評為最有價值企業排行第12名和制藥、生物科技與生命科學行業最具創新力企業第1名。

公司始終秉承“自主創新是企業第一生産力”的發展理念，倡導“坦誠、理解、尊重、信任”的企業文化，擁有一流的人才隊伍，公司及子公司現有員工380餘人，科研人員的比例高達30％以上。此外，還擁有一支由多位國際著名權威學者組成的專家團隊，并與多家國際頂尖科研機構、大學院校和專業化公司建立了廣泛、長期的合作。

目前，公司擁有從基因克隆、蛋白表達與制備、抗體制備到細胞培養等一系列專業化實驗平台，建有符合國家GMP要求的藥品研發中試車間和符合ISO13485标準的診斷試劑生産車間。在診斷試劑研發方面，具備成熟的酶聯免疫吸附( ELISA ) 、免疫印迹（ImmunoBlotting）和膠體金（GICA）等工藝平台；在原料制備方面，具備大腸肝菌表達系統技術平台、酵母表達系統技術、大規模發酵及複性純化技術、CHO細胞表達系統技術、大規模瞬時基因表達技術、雜交瘤技術、大規模動物細胞培養技術。

公司現有十多個産品已獲得了藥監局的生産注冊證并上市銷售。自主研發的酶聯免疫診斷試劑産品、膠體金診斷試劑産品，被認定為上海市高新技術成果轉化項目、上海市自主創新産品。公司還承擔了多項國家級重點科研課題和項目 ，其中包括國家新藥創制重大專項、國家創新基金、上海重大專項基金等 。公司目前已擁有近40 項發明專利，也因此獲得了上海市專利示範企業的殊榮。

強大的科研團隊和持續的研發投入為公司建立具有自主知識産權的高新技術産品體系打下了堅實基礎。公司自主研發的系統性紅斑狼瘡、類風濕關節炎、自身免疫性肝炎等新型診斷試劑自投入市場以來，受到廣大客戶的廣泛好評和高度認同，銷售收入每年高速遞增，并已形成了基本覆蓋全國的營銷網絡，建立了良好的品牌知名度和美譽度，也在國外廠商林立、競争極為激烈的新型診斷試劑産品市場中為國有自主品牌赢得了一席之地。

“科無界，新無限，永争先”，這不僅是6766网站澳门联合娱乐官网平台的口号，更是6766网站澳门联合娱乐官网平台不變的追求。公司一直恪守“以科技創造價值，以創新引領未來，以品質立信社會，以健康奉獻大衆”的經營理念，緻力于将公司發展成為行業内“成長最快、品質最好、品牌最優”的極具競争力的生物企業。曾經、現在和未來，6766网站澳门联合娱乐官网平台人将始終保持一顆竭誠服務社會的赤子之心，立志以一流的産品和服務為大衆提供最為優質的健康産品，也為人類生命科學的不斷發展做出積極貢獻!

Established in April 2008 and located in Shanghai Pudong ZhangJiang High Technology Park, Shanghai Kexin Biotech Co. Ltd., is a public hi-tech company specializing in the development, manufacture and marketing of clinical diagnostic and biological products. Our products and services include biological medicines, innovative In Vitro diagnostic kits and Contract R&D. Our company was successfully listed in the National Equities Exchange and Quotations system (the New Third Board Over the Counter System) in December 2012 (Name: Kexin Biotech, Code: 430175). After a few years of rapid growth, we have now acquired three subsidiary companies. They are Beijing Jin Hao Pharmaceutical Co., Ltd, Zhongshan Ruifu Medical Devices Technology Co., Ltd and Zhongshan Ruifu Medical Device Research Co., Ltd. In 2015, during the New Third Board “Most Valuable and Most Innovative Corporations Contest”, from thousands of companies participated, our company was ranked No. 12 in the “Most Valuable Corporation Rank” and Amazing No.1 in the “Most Innovative Corporation Rank” of Pharmaceutics, Bio-tech and Life Science Industry.
Kexin’s continued success is based on the fact, that as a company, “Independent Innovation is our company’s most important competitive advantage.” Our business culture, “Genuineness, Comprehension, Respect and Trust”, has been attracting many talented people, which have become our most valuable assets now. We now have over 380 employees and more than 30% are R&D staff. Besides, we have top level professional teams consists of multinational world-famous scientists and engineers. Therefore, we have been able to cooperate with many world renowned research institutes, universities and companies, building a wide and effective cooperation network.
Kexin’s basic technology platforms include Genetic Engineering, Protein Expression and Purification, Antibodies production and Mammalian Cell Cultivation. We have established a pilot plant, which complies with cGMP, for biological pharmaceutics trial production. We have established a production plant of In Vitro diagnostic (IVD) test kits, which complies with the ISO13485. The IVD kits we manufacture are based on the ELISA, Immunoblotting and GICA techniques. Furthermore, we specialize in the development and production of recombinant and native antigens, using proprietary technologies. The production platforms range from Prokaryotes to Eukaryotes as well as In Vitro production.
Kexin’s IVD kits are approved by China Food and Drug Administration (CFDA). The ELISA kits and GICA kits we developed have been certified as “Shanghai hi-tech achievements transformation project” as well as “Shanghai Self-dependent Innovative products”. We have participated and undertaken a number of National Key Research Projects including National Major New Drugs Innovation and Development, National Innovative Funds, Shanghai Major Special Fund and many others. We now have over 40 patents awarded, and are certified as Shanghai Patent Demonstration Enterprise.
Kexin’s continuous investment in R&D and our top level scientific teams grant us the capacity to manufacture proprietary and cutting edge products. Our innovative IVD kits are widely used in the clinical laboratory and point-of-care segments of the diagnostic market for systemic lupus erythematosus (SLE), Rheumatoid Arthritis (RA), Autoimmune Liver Disease (ALD) and other autoimmune diseases. These kits have gained in high reputation. Sales revenue has been growing rapidly. After years of efforts, our nationwide marketing network has been established. Kexin brand has now been recognized and we have achieved a favorable position in the heavily competitive market place where major players are multinational- corporations.
“Science without boundary, Inovation without limit and Being first as always”, are our slogans, and moreover, our perpetual quest. Kexin is dedicated to the business philosophy that we “create value using science and technology, lead the future trend by innovation, win the trust of society with high quality products and make a commitment to the public with health”. We are devoted to the establishment of a better and more competitive Kexin Biotech, which has “Fastest growth, Best Quality and Best Brand”. Kexin has now established sterling reputation among the clinical community, a reputation built on innovative products, customer service and attention to detail. Driven by the commitment to the society, Kexin will keep on providing best quality health products to the public, contributing greatly to life science research and development, and most important, making a difference to the world.